Stereotaxis, Inc. reported a decline in financial performance for the first quarter of 2026, with total revenue decreasing by 16% to $6.3 million compared to $7.5 million in the same period of 2025. Revenue from system sales fell to $1.3 million from $2.0 million, attributed to reduced sales volume. Additionally, revenue from disposables, services, and accessories decreased by approximately 10% to $5.0 million, primarily due to the transition from Johnson & Johnson's catheter products to Stereotaxis's proprietary MAGiC catheter. The company's gross margin improved to 60%, up from 54% in the previous year, largely due to a favorable product mix.
Operating expenses for the quarter were slightly lower, totaling $9.8 million compared to $10.0 million in the prior year. Research and development expenses increased marginally to $2.4 million, while sales and marketing expenses decreased to $2.6 million due to lower headcount-related costs. General and administrative expenses rose to $4.8 million, driven by changes in contingent consideration expenses and costs associated with the pending acquisition of Robocath. The net loss attributable to common stockholders was $6.2 million, slightly higher than the $6.1 million loss reported in the same quarter of 2025.
Stereotaxis continues to expand its product offerings and market presence. The company received FDA 510(k) clearance for its GenesisX RMN System and the MAGiC catheter in January 2026, enhancing its portfolio of robotic magnetic navigation systems. Additionally, the company announced plans to acquire Robocath, a French innovator in robotic technology for interventional cardiology, for $20 million, with the transaction expected to close by the end of the third quarter of 2026. This acquisition aims to bolster Stereotaxis's capabilities in the interventional market.
As of March 31, 2026, Stereotaxis reported $14.6 million in cash and cash equivalents, an increase from $13.4 million at the end of 2025. The company generated approximately $4.7 million in cash from financing activities during the quarter, primarily from an at-the-market offering program. However, cash used in operating activities increased to $3.4 million, reflecting changes in working capital. The company anticipates continued investment in research and development and marketing initiatives, which may lead to further losses in 2026 as it seeks to advance the adoption of its technologies.
Looking ahead, Stereotaxis plans to focus on regulatory approvals and the commercialization of its products in various markets. The company acknowledges potential risks from macroeconomic factors, including supply chain disruptions and inflationary pressures, which could impact its operations and financial results. Despite these challenges, Stereotaxis remains committed to expanding its market share and enhancing its product offerings in the interventional cardiology space.
About Stereotaxis, Inc.
Stereotaxis designs and markets robotic systems for minimally invasive interventional procedures, primarily in electrophysiology and cardiology. Its core products include magnetic navigation systems, integrated information solutions, and compatible disposable devices. The company enhances procedural precision, safety, and efficiency, enabling complex treatments with broader physician access. Operating globally, it leverages strategic partnerships, regulatory expertise, and innovative R&D to advance robotic medical technology.
About 10-Q Filings
A 10-Q form is an important financial report that public companies in the United States must submit every three months. It gives a clear picture of a company's financial health and recent performance.
Key points about the 10-Q:
- Frequency: Companies file it three times a year, covering the first three quarters. The fourth quarter is covered in a more comprehensive annual report.
-
Content: It includes:
- Financial statements showing the company's current financial position
- Updates from management on the performance and projections of the business
- Information about potential risks the company faces
- Details on how the company is run internally
- Deadline: Must be filed within 40 or 45 days after the quarter ends, depending on the size of the company.
Our Methodology
AssetRoom is committed to providing timely summaries of news from public companies. We use AI to generate these summaries quickly, but they are not reviewed by human experts.
Our method:
- Data Collection: We continuously monitor for new filings (currently limited to US-listed stocks).
- AI-Powered Analysis: Our advanced AI system processes each filing, identifying key information and extracting relevant data.
- Summary Generation: The AI creates a concise, easy-to-understand summary of the filing, highlighting the most important points.
- Publication: The summary is immediately published on our platform, allowing users instant access to the latest information.
- Email users: We distribute round-up emails according to our users preferences, keeping them in the loop with the companies they follow.
Feedback & Corrections
Spot an error or have a suggestion? Contact us.